MedicineEurope PMC
Ranked by formulaVerdict: MajorRavulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial
In patients with IgA nephropathy, complement activation drives glomerular inflammation, which leads to hematuria, proteinuria, and nephron loss.
Key numbers
- 99% confidence interval
- 69.5% of the patients receiving
- 75.8% of those receiving placebo
VerdictA leading story on any desk.
Abstract
Background In patients with IgA nephropathy, complement activation drives glomerular inflammation, which leads to hematuria, proteinuria, and nephron loss. Ravulizumab is a terminal complement inhibitor that prevents formation of C5a and C5b-9. Methods In this phase 3 trial, we enrolled adults with IgA nephropathy who had an estimated glomerular filtration rate of at least 30 ml per minute per 1.73 m2 of body-surface area and proteinuria (24-hour urinary protein-to-creatinine ratio [with protein and creatinine both measured in grams] of ≥0.75 or total urinary protein excretion of ≥1.0 g per day), despite standard therapy. Patients were randomly assigned in a 1:1 ratio to receive an intravenous infusion of either ravulizumab or placebo every 8 weeks. In the prespecified interim analysis, the primary efficacy end point was the change from baseline in the 24-hour urinary protein-to-creatinine ratio at week 34. Safety was also assessed. Results In all, 485 patients underwent randomization, with 240 patients assigned to the ravulizumab group and 245 to the placebo group; 352 patients (176 in each group) were included in the interim analysis. In the ravulizumab group, the geometric mean 24-hour urinary protein-to-creatinine ratio at baseline and at week 34 was 1.56 and 0.83, respectively; in the placebo group, it was 1.60 and 1.48, respectively. At week 34, a significant reduction in the geometric mean 24-hour urinary protein-to-creatinine ratio was observed with ravulizumab (-46.6%) as compared with the reduction observed with placebo (-5.6%), corresponding to an adjusted geometric mean 24-hour urinary protein-to-creatinine ratio that was 43.4% (99% confidence interval, 30.1 to 54.2) lower with ravulizumab than with placebo (P<0.001). Adverse events occurred in 69.5% of the patients receiving ravulizumab and in 75.8% of those receiving placebo; serious adverse events occurred in 4.6% and 9.0%, respectively. No meningococcal infections or deaths occurred. Conclusions In adults with IgA nephropathy, ravulizumab resulted in a significantly greater reduction in the protein-to-creatinine ratio than placebo at week 34. (Funded by Alexion, AstraZeneca Rare Disease Unit; I CAN ClinicalTrials.gov number, NCT06291376; EU Clinical Trials number, 2023-507851-31-00.).
The editor's rubric
- Leverage2 / 5
- Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
- Magnitude3 / 5
- Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
- Evidence5 / 5
- Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.
- Novelty3 / 5
- A genuinely new approach to an open problem.
- Trajectory2 / 5
- Some room to improve with obvious engineering.
- Stakes3 / 5
- Meaningful benefit to many people within a few years.
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: gains (relative gain); design (randomized, placebo-controlled, phase 3); verification (confidence interval, p-value); stakes (mortality, major disease, prevention or cure).
How the score was computed
Desks place stronger verdicts first, then use this score to order work within the same verdict.
- Merit
- 7.0 / 10
- Adjusted merit
- 5.5 / 10
- Attention
- 0%
- Freshness
- 85%
- Citations0 (reference 20, via openalex, Oct 25, 2026, 06:17 UTC)